



Express Mail No.: EV335858129US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Young et al.

Confirmation No.: 3847

Application No.: 09/996,265

Group Art Unit: 1648

Filed: November 28, 2001

Examiner: Chen, Stacy B.

For: METHODS OF ADMINISTERING/  
DOSING ANTI-RSV ANTIBODIES  
FOR PROPHYLAXIS AND  
TREATMENT

Attorney Docket No.: 10271-048-999

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.56 AND §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references **DL-DU** listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant." Copies of references **DL-DU** are submitted herewith.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Consequently, Applicants respectfully decline to use form PTO-1449, since this form identifies all of the references cited therein as "Prior Art." As an alternative, Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited" instead of "List of Prior Art Cited."

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

01/02/2004 WASFAW1 00000110 161150 09996265  
02 FC:1806 180.00 DA

**BEST AVAILABLE COPY**

Pursuant to 37 C.F.R. §§ 1.97(c) and 1.17(p), Applicants estimate that a fee of \$180.00 is due in connection with the filing of this Information Disclosure Statement. Please charge the required fee to Pennie & Edmonds Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date December 22, 2003

Anthony M. Inogna 35,203  
Anthony M. Inogna (Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

Enclosures

By: Jennifer J. Chedra  
Reg. No. 46,617

**BEST AVAILABLE COPY**

<p><b>LIST OF REFERENCES CITED BY APPLICANT</b>            (Use several sheets if necessary)</p> <p>O I P E            DEC 22 2003            5C53</p>	<b>ATTY DOCKET NO.</b>	<b>APPLICATION NO</b>
	10271-048-999	09/996,265
	<b>APPLICANT</b>	
	Young et al.	
<b>FILING DATE</b>	<b>GROUP</b>	
November 28, 2001	1648	

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

**OTHER REFERENCES** (*Including Author, Title, Date, Pertinent Pages, Etc.*)

	DO	Hacking et al., 2002, "Respiratory syncytial virus - viral biology and the host response," J. Infection 45:18-24
	DP	Heard et al., 1999, "Two neutralizing human RSV antibodies: cloning, expression, and characterization," Mol. Med. 5:35-45
	DQ	Landry et al., "Evaluation of reconstituted lophilized palivizumab given intravenously at 15 and 30 mg/kg," Poster Session, Tuesday, Infect. Dis. 166A: 969
	DR	Saez-Llorens et al., 1997, "Phase I/II open label multi dose escalation trial of a humanized respiratory syncytial virus (RSV) monoclonal antibody (Medi-493) administered intramuscularly (IM) in high risk children," Abstracts in Non HIV virology, ICAAC Toronto
	DS	Subramanian et al., 1997, "Randomized double blind placebo controlled dose escalation trial of a humanized respiratory syncytial virus monoclonal antibody in hugh risk infants," Poster session infect. djs. 130A:768
	DT	Sorbera et al., 1998, "Palivizumab," Drugs of the Future 23:970-976
	DU	Sorbera et al., 1998, "Palivizumab," Drugs Data Report 20:702-703

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**BEST AVAILABLE COPY**